An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma

Trial Profile

An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs BAL 101553 (Primary)
  • Indications Cholangiocarcinoma; Glioblastoma; Glioma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 10 Aug 2017 According to a company media release, Basilea anticipates completing patient recruitment into the this trial by end of this year. Completion of patient recruitment into the separate glioblastoma study arm is expected in the first half of 2018.
    • 12 Jun 2017 According to a Basilea Pharmaceutica Ltd. media release, the Adult Brain Tumor Consortium (ABTC) will conduct a the phase 1 part of this study.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top